We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Pioneering COVID-19 Testing Platform Combines Saliva-Based Sampling, Pooled Testing and PCR Diagnostics

By LabMedica International staff writers
Posted on 09 Mar 2021
A pioneering COVID-19 testing platform combines saliva-based sampling, pooled testing and PCR diagnostics to enable high-quality, high-throughput, low-cost detection of SARS-CoV-2.

Mirimus, Inc.’s (Brooklyn, NY, USA) SalivaClear platform is designed to provide a SARS-CoV-2 diagnostic system that can be easily and repeatedly utilized by myriad organizations, from schools to businesses to government organizations, to test (and retest) groups of individuals in order to quickly isolate COVID-19 hotspots before they can become outbreaks. More...
Mirimus has innovated high-volume COVID-19 PCR testing with SalivaClear, a three-stage surveillance and individual reflex testing strategy to monitor and detect infection in populations by testing people in groups called pools. All three-stages of testing are performed with only one self-collected saliva sample.

For collecting the sample, Mirimus uses a simple self-collection method that is composed of a 2 mL cryogenics vial and saliva collection aid (straw). The saliva straw fits into a cryogenic vial and the testing individual deposits 1 mL of saliva through the straw into the vial. 1 mL of saliva is required for pool testing, subpool testing, and individual diagnostic testing. The individual samples are then shipped to Mirimus' lab where they are pooled into groups of 24 and analyzed using the FDA Emergency Use Authorized ThermoFisherScientific TaqPathCOVID-19 Combo RT-PCR Kit. The pooled test results are typically reported within 24 hours of sample receipt at the laboratory. If a pool tests positive, it is split into 12 pools of two, which are re-tested at the laboratory. If a positive signal emerges from a two-sample pool, the two individuals are asked to provide consent for a final test to determine individual positivity. SalivaClear has been shown to substantially reduce the cost associated with PCR testing and allow schools to rapidly assess transmission and make data-driven decisions to adjust prevention protocols.

"Colleges and universities have, unfortunately, been associated with a substantial number of COVID-19 cases across the country, with a recent report from The New York Times suggesting that more than 120,000 COVID-19 cases have been linked to American colleges and universities since January 1st," said Prem Premsrirut, M.D., Ph.D., Co-founder and CEO of Mirimus. "Given this, the robust surveillance testing that SalivaClear provides is essential to ensuring a safe on-campus learning environment by enabling campus health administrators to quickly isolate hotspots before they can become outbreaks."

Related Links:
Mirimus, Inc.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.